Log In
Print
BCIQ
Print
Print this Print this
 

CAT-1004

  Manage Alerts
Collapse Summary General Information
Company Catabasis Pharmaceuticals Inc.
DescriptionConjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B (NF-kB)
Molecular Target Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50)
Mechanism of ActionNF-kappa B (NF-kB) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today